Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
MarketWatch· Steve Goldstein· Aug 27, 2026 · 8:37 AM
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
This is a summary. Read the complete story at MarketWatch below.
Read full article at MarketWatchRelated Stories
marketsabout 4 hours ago
A new bill in Congress would lower the retirement age to 60. See who would qualify.
A new bill calling for lowering Social Security’s full retirement age from 67 to 60 for workers in physically demanding jobs could put additional strain on the trust fund that backs the system and create a two-tiered system among workers, retirement experts said.
MarketWatch
marketsabout 6 hours ago
‘We lived within our means’: I earned $30,000 as a pastor and still retired comfortably. Why don’t you tell people that?
“As a country, we have grown dangerously comfortable.”
MarketWatch
marketsabout 6 hours ago
Why bond-market volatility hasn’t spilled over into stocks
The bond market has a reputation for being boring. But lately, it has been the source of much of the action in the U.S.
MarketWatch